Index RUT
P/E -
EPS (ttm) -1.57
Insider Own 32.59%
Shs Outstand 70.45M
Perf Week 18.00%
Market Cap 1.78B
Forward P/E -
EPS next Y -2.05
Insider Trans 2.04%
Shs Float 62.97M
Perf Month 7.58%
Income -100.16M
PEG -
EPS next Q -0.39
Inst Own 64.22%
Short Float 9.15%
Perf Quarter 6.62%
Sales 0.00M
P/S -
EPS this Y -8.84%
Inst Trans 17.24%
Short Ratio 7.96
Perf Half Y 178.33%
Book/sh 4.53
P/B 4.20
EPS next Y -19.06%
ROA -28.33%
Short Interest 5.76M
Perf Year 98.85%
Cash/sh 3.41
P/C 5.58
EPS next 5Y -
ROE -30.10%
52W Range 5.12 - 20.69
Perf YTD 73.77%
Dividend Est. -
P/FCF -
EPS past 5Y -68.02%
ROI -30.98%
52W High -8.12%
Beta 0.16
Dividend TTM -
Quick Ratio 19.50
Sales past 5Y 0.00%
Gross Margin -
52W Low 271.29%
ATR (14) 1.25
Dividend Ex-Date -
Current Ratio 19.50
EPS Y/Y TTM -24.21%
Oper. Margin 0.00%
RSI (14) 67.22
Volatility 10.03% 7.61%
Employees 88
Debt/Eq 0.02
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 32.60
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q -51.60%
Payout -
Rel Volume 1.36
Prev Close 17.94
Sales Surprise -
EPS Surprise -8.10%
Sales Q/Q -
Earnings Feb 22 BMO
Avg Volume 723.78K
Price 19.01
SMA20 16.19%
SMA50 13.30%
SMA200 77.93%
Trades
Volume 984,907
Change 5.96%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-07-24 Initiated
Piper Sandler
Overweight
$48
May-01-23 Initiated
Truist
Buy
Aug-25-22 Downgrade
Goldman
Neutral → Sell
$5
Apr-13-22 Initiated
RBC Capital Mkts
Outperform
$31
Jan-28-22 Initiated
Goldman
Neutral
$11
Apr-23-24 09:34AM
08:00AM
Apr-15-24 04:05PM
Mar-28-24 08:00AM
Mar-27-24 08:00AM
08:00AM
Loading…
Mar-05-24 08:00AM
Feb-28-24 08:00AM
Feb-26-24 09:55AM
Feb-22-24 08:00AM
Feb-21-24 09:21AM
Feb-13-24 08:00AM
Feb-11-24 02:55PM
Feb-09-24 09:55AM
Jan-25-24 10:04PM
Jan-24-24 09:55AM
02:06PM
Loading…
Jan-22-24 02:06PM
Jan-19-24 08:37AM
Jan-16-24 09:00AM
Jan-09-24 08:39AM
Dec-29-23 11:02PM
Dec-19-23 08:00AM
Dec-18-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 07:29AM
Nov-09-23 09:41AM
08:00AM
Nov-08-23 08:00AM
Nov-01-23 08:00AM
Oct-26-23 08:00AM
Oct-10-23 09:55AM
08:00AM
Loading…
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-14-23 08:00AM
Sep-05-23 09:55AM
Aug-31-23 10:12PM
Aug-16-23 09:55AM
Aug-10-23 08:00AM
Jul-17-23 12:51PM
Jun-27-23 09:43AM
Jun-26-23 04:01PM
Jun-06-23 08:00AM
May-11-23 08:00AM
May-02-23 08:00AM
Mar-30-23 04:01PM
Mar-21-23 08:00AM
Mar-14-23 08:00AM
Mar-06-23 08:00AM
Mar-01-23 08:00AM
Feb-28-23 08:00AM
Feb-23-23 08:00AM
Feb-07-23 09:39AM
08:00AM
Jan-04-23 08:30AM
Dec-21-22 09:00AM
Dec-20-22 09:00AM
Nov-14-22 09:55AM
Nov-09-22 08:00AM
Nov-03-22 08:00AM
Oct-27-22 04:05PM
Oct-25-22 12:00PM
09:55AM
Oct-13-22 04:30PM
Oct-06-22 08:00AM
Sep-23-22 06:35PM
Sep-16-22 04:05PM
Sep-13-22 09:17PM
05:04PM
08:49AM
Sep-11-22 05:00PM
Sep-07-22 08:00AM
Aug-31-22 08:30AM
Aug-04-22 08:00AM
Aug-03-22 08:00AM
Jul-18-22 11:44AM
Jul-12-22 08:00AM
Jun-22-22 01:53PM
Jun-21-22 08:47AM
Jun-20-22 08:00AM
Jun-16-22 08:00AM
May-31-22 08:00AM
May-11-22 08:00AM
May-03-22 08:00AM
Apr-28-22 11:45AM
Apr-14-22 08:00AM
Mar-24-22 11:11AM
Mar-08-22 08:00AM
Feb-24-22 08:00AM
Feb-03-22 04:35PM
Feb-02-22 09:00AM
Jan-10-22 07:40PM
Jan-05-22 09:15AM
08:00AM
Dec-15-21 09:00AM
Nov-17-21 09:00AM
Nov-10-21 08:00AM
Nov-04-21 11:23AM
Oct-28-21 07:29AM
06:00AM
Oct-11-21 03:56PM
Oct-06-21 11:45AM
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MOORE JOHN R General Counsel Feb 09 '24 Option Exercise 1.93 8,029 15,496 8,029 Feb 09 05:43 PM Derakhshan Behrad Chief Business Officer Feb 09 '24 Option Exercise 1.93 4,800 9,264 11,820 Feb 09 05:42 PM MOORE JOHN R General Counsel Feb 09 '24 Sale 20.01 8,029 160,657 0 Feb 09 05:43 PM Derakhshan Behrad Chief Business Officer Feb 09 '24 Sale 20.04 4,800 96,209 7,020 Feb 09 05:42 PM Derakhshan Behrad Chief Business Officer Feb 08 '24 Option Exercise 1.93 4,600 8,878 11,620 Feb 09 05:42 PM MOORE JOHN R General Counsel Feb 08 '24 Option Exercise 1.93 3,813 7,359 3,813 Feb 09 05:43 PM Derakhshan Behrad Chief Business Officer Feb 08 '24 Sale 20.01 4,600 92,049 7,020 Feb 09 05:42 PM MOORE JOHN R General Counsel Feb 08 '24 Sale 20.01 3,813 76,285 0 Feb 09 05:43 PM MOORE JOHN R General Counsel Feb 07 '24 Option Exercise 1.93 17,993 34,726 17,993 Feb 09 05:43 PM Derakhshan Behrad Chief Business Officer Feb 07 '24 Option Exercise 1.93 600 1,158 7,620 Feb 09 05:42 PM MOORE JOHN R General Counsel Feb 07 '24 Sale 20.00 17,993 359,864 0 Feb 09 05:43 PM Derakhshan Behrad Chief Business Officer Feb 07 '24 Sale 20.00 600 12,000 7,020 Feb 09 05:42 PM Carruthers R Michael Chief Financial Officer Jan 23 '24 Option Exercise 1.93 90,000 173,700 119,024 Jan 25 04:46 PM ORBIMED ADVISORS LLC Director Jan 23 '24 Buy 11.00 454,545 4,999,995 14,436,497 Jan 25 04:28 PM Thompson Peter A. Director Jan 23 '24 Buy 11.00 454,545 4,999,995 14,436,497 Jan 25 04:32 PM Carruthers R Michael Chief Financial Officer Jan 23 '24 Sale 15.78 90,000 1,419,759 29,024 Jan 25 04:46 PM MOORE JOHN R General Counsel Dec 27 '23 Sale 10.50 8,497 89,218 0 Dec 28 04:39 PM Fox Jonathan C Director Dec 26 '23 Buy 9.30 10,857 100,958 10,857 Dec 28 04:39 PM Russell Alan J Chief Scientific Officer Dec 26 '23 Sale 9.33 172,585 1,610,097 3,606 Dec 28 04:38 PM Carruthers R Michael Chief Financial Officer Jun 22 '23 Option Exercise 0.71 10,000 7,100 29,024 Jun 26 04:28 PM Donovan Joanne M. CMO May 02 '23 Sale 8.90 3,254 28,977 9,960 May 03 06:25 PM KOCH KEVIN President and CEO May 02 '23 Sale 8.90 3,203 28,522 7,213 May 03 06:25 PM MOORE JOHN R General Counsel May 02 '23 Sale 8.90 1,897 16,893 6,565 May 03 06:26 PM Derakhshan Behrad Chief Business Officer May 02 '23 Sale 8.90 1,747 15,557 7,020 May 03 06:26 PM Russell Alan J Chief Scientific Officer May 02 '23 Sale 8.90 1,602 14,266 176,191 May 03 06:26 PM Carruthers R Michael Chief Financial Officer May 02 '23 Sale 8.90 1,336 11,897 16,126 May 03 06:26 PM
Index RUT
P/E -
EPS (ttm) -0.69
Insider Own 27.77%
Shs Outstand 60.35M
Perf Week 0.05%
Market Cap 4.24B
Forward P/E -
EPS next Y -1.96
Insider Trans -16.46%
Shs Float 47.36M
Perf Month 64.75%
Income -32.18M
PEG -
EPS next Q -0.43
Inst Own 68.98%
Short Float 10.01%
Perf Quarter 142.77%
Sales 58.88M
P/S 71.93
EPS this Y -174.80%
Inst Trans 37.66%
Short Ratio 2.16
Perf Half Y 560.53%
Book/sh 5.43
P/B 11.89
EPS next Y -11.44%
ROA -9.63%
Short Interest 4.74M
Perf Year 762.48%
Cash/sh 4.99
P/C 12.94
EPS next 5Y -
ROE -12.69%
52W Range 6.71 - 64.72
Perf YTD 238.93%
Dividend Est. -
P/FCF -
EPS past 5Y 24.56%
ROI -9.55%
52W High -0.19%
Beta 0.97
Dividend TTM -
Quick Ratio 7.86
Sales past 5Y 171.70%
Gross Margin 99.02%
52W Low 862.74%
ATR (14) 1.57
Dividend Ex-Date -
Current Ratio 7.86
EPS Y/Y TTM 58.73%
Oper. Margin -75.16%
RSI (14) 82.74
Volatility 0.20% 3.72%
Employees 142
Debt/Eq 0.03
Sales Y/Y TTM 95.84%
Profit Margin -54.66%
Recom 2.75
Target Price 65.00
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q 124.03%
Payout -
Rel Volume 1.23
Prev Close 64.59
Sales Surprise 238.91%
EPS Surprise 145.45%
Sales Q/Q 1011.42%
Earnings Mar 18 AMC
Avg Volume 2.19M
Price 64.60
SMA20 13.72%
SMA50 44.42%
SMA200 182.65%
Trades
Volume 2,690,785
Change 0.02%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-09-24 Initiated
Guggenheim
Buy
$55
Feb-15-24 Initiated
Wolfe Research
Outperform
$44
Oct-18-23 Initiated
Berenberg
Buy
$18
Oct-17-23 Initiated
Berenberg
Buy
$18
Oct-05-23 Initiated
RBC Capital Mkts
Outperform
$19
Jun-26-23 Resumed
Oppenheimer
Outperform
$14
Jan-19-23 Initiated
Morgan Stanley
Overweight
$17
Nov-21-22 Initiated
SVB Leerink
Outperform
$15
Dec-21-20 Initiated
H.C. Wainwright
Buy
$21
Aug-26-20 Initiated
Cowen
Outperform
Apr-25-24 11:28AM
Apr-18-24 08:30AM
Apr-15-24 03:43PM
09:15AM
Apr-13-24 05:29AM
12:36PM
Loading…
Apr-12-24 12:36PM
10:55AM
(The Wall Street Journal)
Apr-11-24 04:43PM
04:29PM
04:18PM
(Investor's Business Daily)
01:59PM
(The Wall Street Journal)
01:07PM
11:58AM
11:03AM
09:47AM
09:47AM
Loading…
09:47AM
09:39AM
07:34AM
Apr-10-24 10:34PM
07:05PM
05:47PM
(The Wall Street Journal)
05:14PM
(Investor's Business Daily)
04:19PM
04:16PM
04:15PM
04:06PM
04:01PM
01:34PM
Apr-09-24 09:23AM
Apr-01-24 09:00AM
07:45AM
Loading…
Mar-21-24 07:45AM
Mar-20-24 04:30PM
Mar-19-24 08:32AM
06:48AM
(Thomson Reuters StreetEvents)
Mar-18-24 08:53PM
07:25PM
05:31PM
04:05PM
Mar-14-24 08:38AM
Mar-11-24 10:00AM
Mar-07-24 04:30PM
Feb-26-24 04:30PM
Feb-01-24 04:30PM
Dec-21-23 04:15PM
Dec-19-23 09:50AM
Dec-18-23 04:30PM
Dec-06-23 09:55AM
Nov-29-23 09:40AM
Nov-20-23 04:30PM
09:55AM
Nov-17-23 07:44PM
Nov-15-23 09:00AM
Nov-14-23 08:55PM
04:15PM
03:57PM
Nov-13-23 09:00AM
Nov-06-23 09:41PM
06:00AM
Nov-03-23 09:00AM
Nov-02-23 09:00AM
Oct-30-23 10:01AM
09:00AM
Oct-27-23 09:40AM
Oct-23-23 12:00PM
Oct-13-23 09:05AM
Oct-12-23 12:13PM
Oct-11-23 10:15AM
Oct-09-23 11:10AM
Oct-06-23 09:55AM
09:24AM
Oct-04-23 08:17AM
08:00AM
Oct-03-23 07:43AM
Sep-18-23 08:52AM
Sep-12-23 08:30AM
Sep-08-23 09:40AM
Sep-05-23 04:30PM
08:30AM
Aug-30-23 04:30PM
Aug-24-23 08:50AM
Aug-22-23 04:30PM
Aug-17-23 09:55AM
Aug-14-23 04:15PM
Jul-23-23 10:25AM
Jun-22-23 07:43AM
Jun-20-23 07:14PM
May-19-23 04:30PM
May-11-23 04:15PM
May-05-23 07:04AM
May-01-23 04:30PM
Mar-27-23 09:16AM
07:08AM
Mar-24-23 10:02AM
(Thomson Reuters StreetEvents) -8.25%
Mar-23-23 05:35PM
04:05PM
Mar-20-23 04:30PM
Mar-16-23 05:30PM
Mar-15-23 04:30PM
Feb-28-23 04:33PM
Feb-13-23 05:16AM
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which focusses on discovering and developing innovative, protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Topper James N Director Apr 25 '24 Sale 64.57 19 1,227 2,829,347 Apr 29 04:32 PM Rickey James Paul See Remarks Jan 26 '24 Option Exercise 8.30 117,764 977,844 73,764 Jan 29 07:04 PM Rickey James Paul See Remarks Jan 26 '24 Sale 23.32 117,764 2,745,830 0 Jan 29 07:04 PM Rickey James Paul See Remarks Jan 25 '24 Option Exercise 6.51 236 1,536 236 Jan 29 07:04 PM Rickey James Paul See Remarks Jan 25 '24 Sale 22.00 236 5,192 0 Jan 29 07:04 PM GOLD MITCHELL Executive Chairman and CEO Dec 28 '23 Option Exercise 12.74 74,441 948,378 2,675,421 Dec 29 07:32 PM GOLD MITCHELL Executive Chairman and CEO Dec 28 '23 Option Exercise 0.65 1,016 660 1,016 Dec 29 07:32 PM ORBIMED ADVISORS LLC Director Dec 28 '23 Sale 18.35 1,364,849 25,049,034 264,315 Dec 29 04:18 PM Thompson Peter A. Director Dec 28 '23 Sale 18.35 1,364,849 25,049,034 264,315 Dec 29 04:20 PM GOLD MITCHELL Executive Chairman and CEO Dec 28 '23 Sale 20.04 1,016 20,362 0 Dec 29 07:32 PM GOLD MITCHELL Executive Chairman and CEO Dec 27 '23 Option Exercise 0.65 29,573 19,222 29,573 Dec 27 09:07 PM ORBIMED ADVISORS LLC Director Dec 27 '23 Sale 19.96 181,498 3,622,700 406,609 Dec 29 04:18 PM Thompson Peter A. Director Dec 27 '23 Sale 19.96 181,498 3,622,700 406,609 Dec 29 04:20 PM GOLD MITCHELL Executive Chairman and CEO Dec 27 '23 Sale 20.04 29,573 592,717 0 Dec 27 09:07 PM GOLD MITCHELL Executive Chairman and CEO Dec 26 '23 Option Exercise 0.63 24,486 15,436 24,486 Dec 27 09:07 PM GOLD MITCHELL Executive Chairman and CEO Dec 26 '23 Sale 20.22 24,486 495,217 0 Dec 27 09:07 PM GOLD MITCHELL Executive Chairman and CEO Dec 22 '23 Option Exercise 0.45 37,825 17,021 37,825 Dec 27 09:07 PM GOLD MITCHELL Executive Chairman and CEO Dec 22 '23 Sale 20.43 37,825 772,595 0 Dec 27 09:07 PM Rickey James Paul See Remarks Dec 19 '23 Option Exercise 5.02 15,213 76,369 15,213 Dec 21 07:35 PM GOLD MITCHELL Executive Chairman and CEO Dec 19 '23 Option Exercise 0.45 2,402 1,081 2,402 Dec 21 07:34 PM Rickey James Paul See Remarks Dec 19 '23 Sale 19.21 15,213 292,222 0 Dec 21 07:35 PM GOLD MITCHELL Executive Chairman and CEO Dec 19 '23 Sale 20.01 2,402 48,064 0 Dec 21 07:34 PM Rickey James Paul See Remarks Dec 18 '23 Option Exercise 5.02 1,800 9,036 1,800 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 18 '23 Sale 19.00 1,800 34,203 0 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 15 '23 Option Exercise 5.02 45,387 227,843 45,387 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 15 '23 Sale 19.09 45,387 866,383 0 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 14 '23 Option Exercise 5.02 11,600 58,232 11,600 Dec 18 09:20 PM Rickey James Paul See Remarks Dec 14 '23 Sale 19.00 11,600 220,406 0 Dec 18 09:20 PM GOLD MITCHELL Executive Chairman and CEO Dec 12 '23 Option Exercise 0.45 8,613 3,876 8,613 Dec 12 09:02 PM GOLD MITCHELL Executive Chairman and CEO Dec 12 '23 Sale 17.32 41,063 711,026 0 Dec 12 09:02 PM GOLD MITCHELL Executive Chairman and CEO Dec 11 '23 Sale 17.26 68,870 1,189,027 32,450 Dec 12 09:02 PM GOLD MITCHELL Executive Chairman and CEO Dec 08 '23 Sale 17.08 8,067 137,784 101,320 Dec 12 09:02 PM Rickey James Paul See Remarks Dec 06 '23 Option Exercise 3.23 6,446 20,821 6,446 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 06 '23 Sale 16.08 6,446 103,650 0 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 05 '23 Option Exercise 3.23 418 1,350 418 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 05 '23 Sale 16.01 418 6,694 0 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 04 '23 Option Exercise 3.23 63,947 206,549 63,947 Dec 06 07:31 PM Rickey James Paul See Remarks Dec 04 '23 Sale 16.06 63,947 1,026,887 0 Dec 06 07:31 PM Rickey James Paul See Remarks Nov 30 '23 Option Exercise 3.23 700 2,261 700 Dec 01 05:00 PM Rickey James Paul See Remarks Nov 30 '23 Sale 16.00 700 11,200 0 Dec 01 05:00 PM Rickey James Paul See Remarks Nov 06 '23 Option Exercise 3.23 10,989 35,494 18,003 Nov 08 05:20 PM Rickey James Paul See Remarks Nov 06 '23 Sale 16.03 18,003 288,554 0 Nov 08 05:20 PM
Index RUT
P/E -
EPS (ttm) -0.57
Insider Own 58.35%
Shs Outstand 96.41M
Perf Week 12.95%
Market Cap 900.34M
Forward P/E -
EPS next Y -0.32
Insider Trans 0.71%
Shs Float 40.19M
Perf Month 0.54%
Income -54.37M
PEG -
EPS next Q -0.10
Inst Own 37.83%
Short Float 15.15%
Perf Quarter 50.24%
Sales 0.03M
P/S 30011.50
EPS this Y -17.19%
Inst Trans 15.39%
Short Ratio 8.71
Perf Half Y 168.10%
Book/sh 2.39
P/B 3.90
EPS next Y 51.72%
ROA -
Short Interest 6.09M
Perf Year 43.54%
Cash/sh 2.37
P/C 3.94
EPS next 5Y -
ROE -
52W Range 2.55 - 11.27
Perf YTD 70.26%
Dividend Est. -
P/FCF -
EPS past 5Y -1.44%
ROI -23.56%
52W High -17.21%
Beta 0.87
Dividend TTM -
Quick Ratio 96.85
Sales past 5Y -34.76%
Gross Margin -143.33%
52W Low 265.88%
ATR (14) 0.52
Dividend Ex-Date -
Current Ratio 96.85
EPS Y/Y TTM 76.45%
Oper. Margin -225066.67%
RSI (14) 57.64
Volatility 6.35% 5.52%
Employees 26
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -181216.67%
Recom 1.00
Target Price 19.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 85.23%
Payout -
Rel Volume 1.59
Prev Close 8.70
Sales Surprise -
EPS Surprise 49.05%
Sales Q/Q -
Earnings Mar 21 AMC
Avg Volume 698.80K
Price 9.33
SMA20 4.43%
SMA50 5.24%
SMA200 45.47%
Trades
Volume 1,110,396
Change 7.24%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-05-24 Upgrade
Leerink Partners
Market Perform → Outperform
$6 → $18
Feb-20-24 Upgrade
William Blair
Mkt Perform → Outperform
Sep-20-23 Downgrade
William Blair
Outperform → Mkt Perform
Jan-31-23 Initiated
Wedbush
Outperform
$10
Jan-03-23 Initiated
William Blair
Outperform
$17
Dec-13-22 Initiated
SVB Leerink
Outperform
$14
Apr-30-24 09:01AM
Apr-05-24 06:30PM
Apr-03-24 09:01AM
Apr-01-24 12:00PM
Mar-26-24 08:50AM
10:53PM
Loading…
Mar-21-24 10:53PM
05:33PM
04:05PM
Mar-15-24 06:00AM
Mar-07-24 04:05PM
Mar-06-24 09:01AM
Feb-26-24 09:01AM
Feb-22-24 09:01AM
Feb-20-24 09:01AM
Feb-05-24 09:01AM
04:00PM
Loading…
Nov-09-23 04:00PM
11:02AM
Oct-06-23 09:03AM
Oct-03-23 09:03AM
03:01AM
Sep-29-23 07:50PM
01:39PM
10:00AM
10:00AM
Sep-21-23 12:28PM
10:43AM
06:28AM
Sep-20-23 12:42PM
10:31AM
10:26AM
09:49AM
Loading…
09:49AM
(The Wall Street Journal)
06:13AM
Sep-19-23 10:49PM
Sep-08-23 07:10PM
Aug-10-23 04:00PM
Jun-20-23 08:00AM
May-15-23 02:11PM
09:00AM
May-12-23 11:51AM
May-11-23 07:01PM
May-09-23 09:10AM
Apr-21-23 10:05AM
Mar-28-23 09:39AM
Mar-25-23 09:10AM
Mar-23-23 04:01PM
Mar-22-23 06:19AM
Feb-23-23 04:01PM
Feb-22-23 04:05PM
Feb-09-23 06:30AM
05:43AM
Nov-10-22 08:00AM
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Tanimoto Sarina CHIEF MEDICAL OFFICER Apr 23 '24 Option Exercise 1.06 130,993 138,990 3,407,847 Apr 24 06:18 PM Lowenthal Richard E PRESIDENT AND CEO Apr 23 '24 Option Exercise 1.06 130,993 138,990 3,407,847 Apr 24 06:17 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Apr 19 '24 Option Exercise 1.06 188,491 199,999 4,315,313 Apr 22 07:23 PM Lowenthal Richard E PRESIDENT AND CEO Apr 19 '24 Option Exercise 1.06 188,491 199,999 4,315,313 Apr 22 07:22 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Apr 16 '24 Sale 9.28 100,000 928,005 1,647,447 Apr 17 06:42 PM Lowenthal Richard E PRESIDENT AND CEO Apr 16 '24 Sale 9.28 100,000 928,005 1,647,447 Apr 17 06:40 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Apr 09 '24 Sale 9.28 100,000 927,735 1,646,494 Apr 10 05:39 PM Lowenthal Richard E PRESIDENT AND CEO Apr 09 '24 Sale 9.28 100,000 927,735 1,646,494 Apr 10 05:36 PM RA CAPITAL MANAGEMENT, L.P. Director Mar 27 '24 Buy 9.79 505,954 4,953,290 9,958,073 Mar 27 07:37 PM RA CAPITAL MANAGEMENT, L.P. Director Mar 26 '24 Buy 9.55 457,745 4,371,465 9,452,119 Mar 27 07:37 PM RA CAPITAL MANAGEMENT, L.P. Director Mar 25 '24 Buy 9.06 437,600 3,964,656 8,994,374 Mar 27 07:37 PM Lowenthal Richard E PRESIDENT AND CEO Mar 25 '24 Sale 9.12 95,267 869,188 1,697,447 Mar 26 06:48 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Mar 25 '24 Sale 9.12 95,267 869,188 1,697,447 Mar 26 06:47 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Mar 22 '24 Sale 9.02 2,343 21,135 1,745,082 Mar 26 06:47 PM Lowenthal Richard E PRESIDENT AND CEO Mar 22 '24 Sale 9.02 2,343 21,135 1,745,082 Mar 26 06:48 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Mar 21 '24 Sale 9.00 472 4,248 1,746,099 Mar 21 09:50 PM Lowenthal Richard E PRESIDENT AND CEO Mar 21 '24 Sale 9.00 472 4,248 1,746,099 Mar 21 09:51 PM Lowenthal Richard E PRESIDENT AND CEO Mar 19 '24 Sale 9.03 1,918 17,324 1,746,471 Mar 21 09:51 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Mar 19 '24 Sale 9.03 1,918 17,324 1,746,471 Mar 21 09:50 PM Lowenthal Richard E PRESIDENT AND CEO Mar 15 '24 Sale 9.14 96,756 884,485 1,696,494 Mar 15 07:55 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Mar 15 '24 Sale 9.14 96,756 884,485 1,696,494 Mar 15 07:52 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Mar 14 '24 Sale 9.00 444 3,996 1,744,789 Mar 15 07:52 PM Lowenthal Richard E PRESIDENT AND CEO Mar 14 '24 Sale 9.00 444 3,996 1,744,789 Mar 15 07:55 PM Lowenthal Richard E PRESIDENT AND CEO Mar 13 '24 Sale 9.00 2,800 25,200 1,744,994 Mar 15 07:55 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Mar 13 '24 Sale 9.00 2,800 25,200 1,744,994 Mar 15 07:52 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Feb 29 '24 Sale 9.02 3,782 34,101 1,746,494 Mar 01 08:21 PM Lowenthal Richard E PRESIDENT AND CEO Feb 29 '24 Sale 9.02 3,782 34,101 1,746,494 Mar 01 08:17 PM Lowenthal Richard E PRESIDENT AND CEO Feb 28 '24 Sale 9.02 98,778 891,061 1,747,294 Feb 28 09:04 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Feb 28 '24 Sale 9.02 98,778 891,061 1,747,294 Feb 28 09:08 PM Tanimoto Sarina CHIEF MEDICAL OFFICER Feb 26 '24 Sale 9.01 700 6,307 1,772,750 Feb 28 09:08 PM Lowenthal Richard E PRESIDENT AND CEO Feb 26 '24 Sale 9.01 700 6,307 1,772,750 Feb 28 09:04 PM Fitzpatrick Alexander A Chief Legal Officer Sep 29 '23 Buy 3.78 46,258 174,994 89,227 Oct 02 04:23 PM Fitzpatrick Alexander A Chief Legal Officer Sep 28 '23 Buy 3.62 40,000 144,960 42,969 Oct 02 04:23 PM RA CAPITAL MANAGEMENT, L.P. Director Sep 21 '23 Buy 3.03 2,700,000 8,183,526 8,556,774 Sep 25 04:30 PM Shawver Laura Director Sep 01 '23 Option Exercise 1.27 100,000 127,000 310,346 Sep 05 08:04 PM Shawver Laura Director Sep 01 '23 Sale 7.71 100,000 770,520 210,346 Sep 05 08:04 PM RA CAPITAL MANAGEMENT, L.P. Director Aug 29 '23 Buy 6.20 3,750,000 23,250,000 5,856,774 Aug 31 05:26 PM ORBIMED ADVISORS LLC Director Aug 29 '23 Buy 6.20 500,000 3,100,000 8,019,187 Aug 31 05:26 PM Thompson Peter A. Director Aug 29 '23 Buy 6.20 500,000 3,100,000 8,019,187 Aug 31 05:18 PM Shawver Laura Director Aug 04 '23 Option Exercise 1.27 18,897 23,999 229,243 Aug 07 05:05 PM Shawver Laura Director Aug 04 '23 Sale 7.06 18,897 133,471 210,346 Aug 07 05:05 PM Shawver Laura Director Aug 03 '23 Option Exercise 1.27 26,107 33,156 236,453 Aug 07 05:05 PM Shawver Laura Director Aug 03 '23 Sale 7.01 26,107 183,018 210,346 Aug 07 05:05 PM Shawver Laura Director Aug 02 '23 Option Exercise 1.27 36,281 46,077 246,627 Aug 03 06:03 PM Shawver Laura Director Aug 02 '23 Sale 7.09 36,281 257,265 210,346 Aug 03 06:03 PM Shawver Laura Director Aug 01 '23 Option Exercise 1.27 18,715 23,768 229,061 Aug 03 06:03 PM Shawver Laura Director Aug 01 '23 Sale 7.19 18,715 134,576 210,346 Aug 03 06:03 PM Shawver Laura Director Jul 07 '23 Option Exercise 1.27 8,858 11,250 219,204 Jul 07 08:16 PM Shawver Laura Director Jul 07 '23 Sale 6.36 8,858 56,372 210,346 Jul 07 08:16 PM Shawver Laura Director Jul 06 '23 Option Exercise 1.27 33,510 42,558 243,856 Jul 06 08:55 PM Shawver Laura Director Jul 06 '23 Sale 6.34 33,510 212,554 210,346 Jul 06 08:55 PM Shawver Laura Director Jul 05 '23 Option Exercise 1.27 31,112 39,512 241,458 Jul 06 08:55 PM Shawver Laura Director Jul 05 '23 Sale 6.41 31,112 199,552 210,346 Jul 06 08:55 PM Shawver Laura Director Jul 03 '23 Option Exercise 1.27 26,520 33,680 236,866 Jul 06 08:55 PM Shawver Laura Director Jul 03 '23 Sale 6.72 26,520 178,347 210,346 Jul 06 08:55 PM Shawver Laura Director Jun 02 '23 Option Exercise 1.27 26,941 34,215 237,287 Jun 02 07:48 PM Shawver Laura Director Jun 02 '23 Sale 6.95 26,941 187,240 210,346 Jun 02 07:48 PM Shawver Laura Director Jun 01 '23 Option Exercise 1.27 73,059 92,785 283,405 Jun 02 07:48 PM Shawver Laura Director Jun 01 '23 Sale 6.80 73,059 496,801 210,346 Jun 02 07:48 PM Shawver Laura Director May 09 '23 Option Exercise 1.27 42,900 54,483 253,246 May 10 04:53 PM Shawver Laura Director May 09 '23 Sale 5.31 42,900 227,799 210,346 May 10 04:53 PM Shawver Laura Director May 08 '23 Option Exercise 1.27 57,100 72,517 267,446 May 10 04:53 PM Shawver Laura Director May 08 '23 Sale 6.16 57,100 351,736 210,346 May 10 04:53 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite